Biotech company 10x Genomics (NASDAQ:TXG) beat Wall Street’s revenue expectations in Q3 CY2025, but sales fell by 1.7% year on year to $149 million. On top of that, next quarter’s revenue guidance ($156 million at the midpoint) was surprisingly good and 3.5% above what analysts were expecting. Its GAAP loss of $0.22 per share was 22.7% above analysts’ consensus estimates.
Biotech company 10x Genomics (NASDAQ:TXG) reported Q3 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 1.7% year on year to $149 million. On top of that, next quarter’s revenue guidance ($156 million at the midpoint) was surprisingly good and 3.5% above what analysts were expecting. Its GAAP loss of $0.22 per share was 22.3% above analysts’ consensus estimates.
The Chan Zuckerberg Initiative (CZI), founded by Priscilla Chan and Mark Zuckerberg, is placing artificial intelligence at the very heart of its audacious mission: to cure, prevent, or manage all diseases by the end of the century. This monumental philanthropic endeavor is not merely dabbling in AI; it's architecting a future where advanced computational models [...]
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry’s 13.5% return has trailed the S&P 500 by 9.4 percentage points.
Shares of biotech company 10x Genomics (NASDAQ:TXG)
jumped 6% in the morning session after BofA Securities maintained its "Buy" rating on the stock, even while lowering its price target.
Shares of biotech company 10x Genomics (NASDAQ:TXG)
jumped 1.5% in the afternoon session after it announced a strategic partnership with SPT Labtech, a laboratory automation company, to provide automated workflows for single-cell research.
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue.
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges.
However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.
Shares of biotech company 10x Genomics (NASDAQ:TXG)
fell 2.4% in the afternoon session after the stock extended its negative momentum as Piper Sandler initiated coverage of the stock with a Neutral rating and a $15.00 price target.
Shares of biotech company 10x Genomics (NASDAQ:TXG)
jumped 2.1% in the morning session after Piper Sandler initiated coverage on the stock with a Neutral rating and a $15.00 price target.
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments.
Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.
A number of stocks fell in the afternoon session after markets pulled back, reversing early gains, as investor sentiment remained cautious despite a softer-than-expected inflation reading.
